Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

The following content is for informational purposes only. This article is not intended to be a substitute for profession ...

Dr. Daniel Benhuri, a board-certified internal medicine and primary care physician, has been named the 2025 Top Patient Rated Primary Care Physician in Beverly Hills by Find Local Doctors. This ...

Doctors say new research has found a link between weight-loss drugs and cancer, putting users at 'significantly higher risk' ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...